The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema

Sponsor
Shahid Beheshti University of Medical Sciences
Study ID
NCT03821168
Phase
PHASE2/PHASE3
Status
Unknown

Conditions

  • Refractory Diabetic Macular Edema

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

after advent of RD photoreceptor degeneration Occurred. This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened . Process of degeneration begins from first hours of RD establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years . How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researches. In the study investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study.

Key Dates

First listed
Jan 29, 2019
Start date
Mar 1, 2019
Status verified
Dec 2018
Primary completion
Apr 1, 2019
Completion
Oct 1, 2019

Study Design

Enrollment
58 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: intravitreal injection of bevacizumab and erythropoietin
    erythropoietin:
  • Active Comparator: intravitreal injection of bevacizumab
    bevacizumab:1.25 mg

Primary Outcome Measure

best corrected visual acuity [ Time Frame: 1 month ]

Central Contacts